Cefoperazone/sulbactam in Treatment of Biliary Tract Infections: A Prospective Multicenter Clinical Trial
LI Zhan-liang,ZHANG Tong-lin,XU Zhi,YANG Lei,LIU Jia-feng,LIANG Li-jian,LAI Jia-ming,ZHANG Ping,PENG Cheng-hong,CHEN Hao,QUAN Zhi-wei,ZHANG Sheng-lai,LIANG Ting-bo,WANG Wei-lin,JIANG Fei-zhao,ZHANG Zhi-wei,ZHANG Bi-xiang,CUI Nai-qiang,FU Qiang,LI Qiang,XIE Min
DOI: https://doi.org/10.3321/j.issn:1005-4529.2008.04.039
2008-01-01
Abstract:OBJECTIVE To evaluate the safety and clinical efficacy of cefoperazone/sulbactam in the treatment of biliary tract infections.METHODS In this prospective multicenter study,159 hospitalized patients with biliary tract infections received cefoperazone/sulbactam,and the clinical and bacteriological efficacy as well as the side effects were evaluated.RESULTS The clinical effective rate of cefoperazone/sulbactam in the treatment of biliary tract infections was 86.78%.After treatment,the body temperature reduced to normal rapidly,the average time of defervescence was 3.09±1.81 days.Pathogen eradication rate was 85.71%.No adverse reactions were reported during the study period.CONCLUSIONS Cefoperazone/sulbactam can be used as one of antibiotics of choice in the initial empirical therapy for biliary tract infections.